Caitlin John’s CRISPR Therapeutics CRSP Stock Holding History

Caitlin John’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-25	Closed	-$1.35K	–	882
2024 Q2	$1.35K	Sell	25 -10	-29%	-$578	﹤0.01%	697
2024 Q1	$2.39K	Hold	35	–	–	﹤0.01%	662
2023 Q4	$2.19K	Buy	+35	New	+$1.94K	﹤0.01%	679

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Caitlin John's CRSP Position: Q3 2024 in Review

Caitlin John sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 25 shares — an estimated $1.35K sold.

Caitlin John first reported a position in CRSP in Q4 2023 and held it in 3 quarters. The position peaked at $2.39K in Q1 2024. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

Caitlin John reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
Caitlin John sold 25 CRISPR Therapeutics shares in Q3 2024, an estimated $1.35K.
Caitlin John first reported a position in CRISPR Therapeutics in Q4 2023 and held it in 3 quarters.
Caitlin John's CRISPR Therapeutics position peaked at $2.39K in Q1 2024.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Caitlin John's 13F filing for Q3 2024, filed 14 Nov 2024.